Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm (ERAMPPCI)

Action slowing has been demonstrated in many diseases. Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting the basal ganglia, particularly the medial globus pallidus, and the clinical expression of these two diseases is characterized by a combination of motor and cognitive disorders, but with two opposing patterns of dysfunction. Action slowing has been demonstrated in both of these diseases and has been extensively studied in Parkinson's disease, suggesting a perceptive-cognitive origin. Far fewer studies have been conducted in Huntington's disease. However, all of these studies were performed with different methodologies in small cohorts and the value of the proposed study is to use a validated and standardized computerized mental chronometry paradigm, providing a better understanding of the mechanisms of action slowing in these two diseases and to more clearly define a disease-specific profile.

Study Overview

• Status: Completed
• Conditions: Parkinson Disease; Huntington Disease
• Intervention / Treatment: Behavioral: SRT

• Study Type: Observational
• Enrollment (Actual): 55

Contacts and Locations

Study Locations

• France
  • Amiens, France, 80054
    • CHU AMIENS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with Hoehn and Yahr stage 1 to 3 Parkinson's disease and patients with Shoulson stage I and II Huntington's disease, in whom admission to the Neurology ward is scheduled in the context of their follow-up, comprising a neuropsychological assessment (together with an acute L-dopa administration test for Parkinsonian patients) will be included

Description

Inclusion Criteria:

• Agreeing to participate in the study
• French mother tongue
• MMSE > 20/30

• Specific to the MP and MH:

  • Parkinson's disease:

    • defined by the criteria of the UKPDSBB
    • stage 1 , 2 or 3 Hoehn and Yahr (ON)
    • age of onset of the disease known
    • brain MRI performed during follow-up

  • Huntington disease :

    • genetically defined (CAG > 35)
    • weaning neuroleptic ( Tercian® and Solian® : 2 days; Haldol® : 5 days ; Tiapridal® and Xenazine : 1 day ; Zyprexa® : 4 days)
    • Early stage : Fahn and Shoulson I and II is a CFT score between 7 and 13

Exclusion Criteria:

• Illiteracy, writing or reading difficulties
• Visual perceptual auditory deficit or preventing reading, drawing, writing or understanding instructions
• Visual hallucinations
• Significant history may sound on cognition (unbalanced thyroid dysfunction, ischemic heart disease or embolic unstabilized or symptomatic, progressive neoplasia, chronic alcoholism weaned or not)
• Current or previous neurological diseases other than MH or MP: ischemic cerebral vascular accident or bleeding, head injuries (loss of higher knowledge in 15 minutes), epilepsy requiring treatment.
• Psychiatric disorders depression unless treated (stable treatment for 1 month)
• Psychotropic treatment (except anxiolytic, antidepressant steady since 1 month)
• Inability to achieve an autonomous operation without technical assistance over a distance of 20 meters.
• Inability to stand without technical assistance for 30 seconds.

Study Plan

How is the study designed?

Number of groups / cohorts

4

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Parkinson best-On; two hours after taking two tablets of 125 mg dispersible Modopar®	Behavioral: SRT; simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )
Parkinson worst-off; after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)	Behavioral: SRT; simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )
Huntington	Behavioral: SRT; simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )
Control; Data collected from the existing database	Behavioral: SRT; simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
SRT	simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase "worst -off" at the Parkinson's patient )	Day 0

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens
• Investigators: Principal Investigator: Pierre KRYSTKOWIAK, MD, PhD, CHU AMIENS

Study record dates

Study Major Dates

• Study Start: July 1, 2011
• Primary Completion (ACTUAL): November 1, 2016
• Study Completion (ACTUAL): November 1, 2016

Study Registration Dates

• First Submitted: June 23, 2016
• First Submitted That Met QC Criteria: June 23, 2016
• First Posted (ESTIMATE): June 27, 2016

Study Record Updates

• Last Update Posted (ESTIMATE): December 5, 2016
• Last Update Submitted That Met QC Criteria: December 2, 2016
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Keywords: Motor slowing; Computerized mental chronometry paradigm
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Genetic Diseases, Inborn; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Dyskinesias; Heredodegenerative Disorders, Nervous System; Dementia; Cognition Disorders; Chorea; Parkinson Disease; Huntington Disease
• Other Study ID Numbers: PI10-DR-DURU